Diffuse cutaneous systemic sclerosis (dcSSc) is an autoimmune disease also known as progressive scleroderma. The BRAVOS clinical trial is currently enrolling scleroderma patients to determine the safety and tolerability of brentuximab vedotin, a drug that is FDA-approved for the treatment of Hodgkin’s and other lymphomas.
The BRAVOS study is being conducted at research centers across the United States. You may be eligible to participate in the BRAVOS study if you:
- Are 18 to 70 years old
- Have been diagnosed with dcSSc
- Have had dcSSc for 5 or fewer years
- Are on ongoing immunosuppressive therapy with one of the following: methotrexate, mycophenolate mofetil or azathioprine